Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory ...
Project: GOLIATH
Updated at: 01-03-2025
Project: GOLIATH
Updated at: 01-03-2025
Project: GOLIATH
Updated at: 01-03-2025
Project: GOLIATH
Updated at: 01-03-2025
Project: GOLIATH
Updated at: 01-03-2025
Project: GOLIATH
Updated at: 01-03-2025
Project: GOLIATH
Updated at: 01-03-2025
Project: GOLIATH
Updated at: 01-03-2025
Project: GOLIATH
Updated at: 31-05-2024
Project: GOLIATH
Updated at: 31-01-2024
Project: GOLIATH
Updated at: 31-01-2024
Project: GOLIATH
Updated at: 31-01-2024
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 14-11-2023
Project: GOLIATH
Updated at: 31-07-2023
Project: GOLIATH
Updated at: 31-07-2023
Project: GOLIATH
Updated at: 31-07-2023
Project: GOLIATH
Updated at: 31-07-2023